Form 4/A for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-14 · accession 0001209191-23-043162 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-07-21 | 2023-07-14 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +25.0K | 95.2K | +36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-14 | A | A | 25,000 | $0.00 | 95,180 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. (F2) This amendment is being filed to correct the transaction price included in the Form 4 filed on behalf of the Reporting Person on July 17, 2023. (F3) Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023. |